CIK细胞治疗晚期恶性肿瘤疗效分析

目的研究自体CIK细胞过继性免疫治疗晚期恶性肿瘤的临床疗效。方法从34例晚期肿瘤患者外周血中分离出单个核细胞,加入含有IFN-γ、IL-2、抗CD3单抗等细胞因子的培养基中进行培养。扩增后的CIK细胞总数在4.5~6×109之间,分三次回输给患者。检测患者回输前后瘤体变化,免疫学指标和肿瘤标志物的改变,观察患者临床症状的改善和毒副反应。结果 34例接受CIK治疗的患者中,外周血中CD3+、CD4+、CD4+/CD8+和NK细胞(CD16、CD56)均显著上升(P0.05),CD8+下降。有效率(CR+PR+MR)为79.4%。24例CEA升高者19例下降,8例CA125升高者6例下降,4例CA199升高者均下降。患者临床症状改善,毒副反应轻。结论自体CIK细胞过继性免疫治疗能显著提高肿瘤患者细胞免疫功能,改善临床症状,提高生活质量。

Analysis on Efficacy of CIK Cells in Advanced Malignant Tumors

Objective To study the clinical efficacy of adoptive immunotherapy with autologous CIK cells in patients with advanced malignant tumors. Methods Peripheral blood mononuclear cells（PBMCs） of 34 patients with advanced malignant tumors were isolated,and then were incubated in vitro with IFN-γ,IL-2 and anti-CD3 monoclonal antibody.The total number of CIK cells per patient expanded about 4.5～6×10^9,and then were transfused back to the patients with three times.The changes of tumor weight,immunity indexes,tumor markers,clinical symptoms,and toxicity in the patients were observed before and after CIK cells being transfused back. Results After being treated with CIK cells,the CD3^＋,CD4^＋,CD4^＋/CD8^＋ and NK cells（CD16,CD56） of 34 patients were increased significantly（P〈0.05）,but CD8^＋ was decreased at the same time.The total efficiency（CR＋PR＋MR） was 79.4%.Among 24 patients with increasing serum CEA level,19 showed a reduction.In 8 patients with increasing serum CA125 level,6 showed a reduction.4 patients with increasing serum CA199 level showed a reduction entirely.The clinical symptoms of the treated patients were improved with little toxicity. Conclusions The adoptive immunotherapy with CIK cells can significantly enhance cellular immune function and improve the quality of life and clinical symptoms for the patients with advanced malignant tumors.